• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    10/30/23 5:31:09 PM ET
    $AKTX
    $ARTL
    $CBIO
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTX alert in real time by email

    Gainers

    • TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 16.7% to $0.42 during Monday's after-market session. Today's trading volume for this security ended up closing at 3.7 million shares, which is 69.6 percent of its average volume over the last 100 days. The company's market cap stands at $5.0 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 16.23% to $0.54. This security traded at a volume of 96.0K shares come close, making up 67.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $8.6 million.
    • Artelo Biosciences (NASDAQ:ARTL) shares increased by 12.69% to $1.42. The market value of their outstanding shares is at $4.0 million.
    • Catalyst Biosciences (NASDAQ:CBIO) stock moved upwards by 7.7% to $0.55. The company's market cap stands at $20.9 million. As per the news, the Q3 earnings report came out 2 days ago.
    • Renalytix (NASDAQ:RNLX) stock moved upwards by 7.61% to $1.13. The company's market cap stands at $55.0 million.
    • Vivani Medical (NASDAQ:VANI) shares moved upwards by 6.48% to $1.15. The company's market cap stands at $58.4 million.

    Losers

    • Orgenesis (NASDAQ:ORGS) stock declined by 32.1% to $0.55 during Monday's after-market session. Trading volume for this security closed at 103.1K, accounting for 106.0% of its average full-day volume over the last 100 days. The company's market cap stands at $16.7 million.
    • GeneDx Hldgs (NASDAQ:WGS) shares decreased by 16.11% to $2.24. The company's market cap stands at $57.7 million. As per the press release, Q3 earnings came out today.
    • Catalent (NYSE:CTLT) shares fell 14.83% to $34.0. Trading volume for this security closed at 687.7K, accounting for 33.2% of its average full-day volume over the last 100 days. The company's market cap stands at $6.1 billion.
    • Sientra (NASDAQ:SIEN) shares decreased by 14.39% to $1.25. The market value of their outstanding shares is at $14.0 million.
    • Regenxbio (NASDAQ:RGNX) shares decreased by 13.02% to $12.5. The market value of their outstanding shares is at $549.5 million.
    • Akari Therapeutics (NASDAQ:AKTX) shares decreased by 9.17% to $3.27. The market value of their outstanding shares is at $16.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTX
    $ARTL
    $CBIO
    $CTLT

    CompanyDatePrice TargetRatingAnalyst
    GeneDx Holdings Corp.
    $WGS
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    REGENXBIO Inc.
    $RGNX
    1/28/2026$37.00Overweight
    Barclays
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    GeneDx Holdings Corp.
    $WGS
    10/20/2025$155.00Buy
    Canaccord Genuity
    Crescent Biopharma Inc.
    $CBIO
    8/25/2025$26.00Buy
    Jefferies
    Crescent Biopharma Inc.
    $CBIO
    8/11/2025$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $AKTX
    $ARTL
    $CBIO
    $CTLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Barclays resumed coverage on REGENXBIO with a new price target

    Barclays resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $37.00

    1/28/26 7:18:39 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $ARTL
    $CBIO
    $CTLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,683,335 worth of shares (1,575,231 units at $1.07) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    3/16/26 6:15:46 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/5/26 7:19:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Williams Gregg bought $1,983,333 worth of shares (1,866,492 units at $1.06) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    2/17/26 6:01:47 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKTX
    $ARTL
    $CBIO
    $CTLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants to purchase up to 6,376,814 shares of common stock, at a combined purchase price of $3.45 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds from the offering were approximately $11.0 million, prior to deducting placement agent fees and other offering expenses payable by the Company. The Com

    3/30/26 4:46:00 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 35,325 shares of the Company's ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on March 26, 2026 and were material to each employee's accept

    3/27/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants to purchase up to 6,376,814 shares of common stock, at a combined purchase price of $3.45 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.20 per share, will be exercisable upon issuance and will expire five and one-half years from the Effectivenes

    3/27/26 10:40:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $ARTL
    $CBIO
    $CTLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Feeley Kevin

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/30/26 5:38:19 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 4 filed by Stueland Katherine

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/30/26 5:30:12 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    CHIEF EXECUTIVE OFFICER Stueland Katherine sold $1,319,291 worth of shares (17,179 units at $76.80) and converted options into 30,671 shares, increasing direct ownership by 30% to 58,447 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/17/26 6:40:58 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $AKTX
    $ARTL
    $CBIO
    $CTLT
    SEC Filings

    View All

    SEC Form 10-K filed by Akari Therapeutics plc

    10-K - Akari Therapeutics Plc (0001541157) (Filer)

    3/30/26 5:39:37 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    3/30/26 5:35:26 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Artelo Biosciences Inc.

    D - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    3/27/26 5:01:04 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $ARTL
    $CBIO
    $CTLT
    Financials

    Live finance-specific insights

    View All

    REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026Robust patient enrollment continues in confirmatory trialSurabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected in Q2 2026Company to engage FDA on potential path forward for RGX-121Conference call today at 8:00 a.m. ETROCKVILLE, Md., March 5, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported financial results and operational highlights f

    3/5/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology comp

    2/25/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

    Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34% year-over-year Reported fourth quarter 2025 adjusted gross margin1 of 71% Reported fourth quarter 2025 adjusted net income1 of $4.4 million Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for t

    2/23/26 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $AKTX
    $ARTL
    $CBIO
    $CTLT
    Leadership Updates

    Live Leadership Updates

    View All

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board (SAB). Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, "Dr. Anczukow is a leading authority in RNA splicing and cancer biology, an area of growing importance for the development of next-generation therapeutics. Her scientific rigor, translational mindset, and experience advancing RNA-focused discoveries toward clinical relevance make her an outstandin

    2/23/26 8:50:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

    Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli

    1/6/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $AKTX
    $ARTL
    $CBIO
    $CTLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:51:18 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:50:26 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care